ReviewWiener medizinische Wochenschrift (1946)2020
Multidisciplinary patient care in X-linked hypophosphatemic rickets: one challenge, many perspectives.
Review in Wiener medizinische Wochenschrift (1946), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Rare disease care pathways profile in France: leveraging hospital big data to characterize natural history in osteogenesis imperfecta.JBMR plus · 2026Article
- Delayed diagnosis of X-linked hypophosphatemia in the absence of family history: a global unmet need.JBMR plus · 2025Article
- Experts' consensus on the management and treatment of individuals with X-linked hypophosphatemia across lifespan.Journal of endocrinological investigation · 2025Article
- XLH Matters 2024: expert insights and practical tools for enhancing care of people living with X-linked hypophosphataemia.Orphanet journal of rare diseases · 2025Article
- Prevalence of enthesopathies in X-linked hypophosphatemia: an explorative ultrasound study.JBMR plus · 2025Article
- XLH Matters: an evolving programme to discuss new advances and share clinical experiences to improve patient outcomes.Orphanet journal of rare diseases · 2025Article
- Areas of uncertainty on the diagnosis, treatment, and follow-up of hypophosphatemia in adults: an Italian Delphi consensus.Journal of endocrinological investigation · 2025Article
- Use of Complementary and Alternative Medicine in Patients with Rare Bone Diseases and Osteoporosis.Nutrients · 2024Article
- Impact of burosumab on lower limb alignment in children with X-linked hypophosphatemia.Journal of the Pediatric Orthopaedic Society of North America · 2024Article
- Diagnosis, treatment, and management of rickets: a position statement from the Bone and Mineral Metabolism Group of the Italian Society of Pediatric Endocrinology and Diabetology.Frontiers in endocrinology · 2024Review
- XLH Matters 2022: Insights and recommendations to improve outcomes for people living with X-linked hypophosphataemia (XLH).Orphanet journal of rare diseases · 2023Article
- Dissociation of clinical, laboratory, and bone biopsy findings in adult X-linked hypophosphatemia: a case report.Wiener medizinische Wochenschrift (1946) · 2023Article
- Growing Taller without Hormones? Dr. Consult Google-An Evaluation of Online Information Related to Limb Lengthening.Healthcare (Basel, Switzerland) · 2023Article
- Article
- Review
- X-linked hypophosphatemic rickets: Case report of late diagnosis and bone pain improvement with targeted treatment.Clinical case reports · 2022Article
- X-linked Hypophosphatemic Rickets: Awareness, Knowledge, and Practice of Pediatric Endocrinologists in Arab Countries.Journal of pediatric genetics · 2022Article
- Health Care Transition From Pediatric- to Adult-Focused Care in X-linked Hypophosphatemia: Expert Consensus.The Journal of clinical endocrinology and metabolism · 2022Article
- Potential influences on optimizing long-term musculoskeletal health in children and adolescents with X-linked hypophosphatemia (XLH).Orphanet journal of rare diseases · 2022Review
- Oral health-related quality of life in patients with X-linked hypophosphatemia: a qualitative exploration.Endocrine connections · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
X‑linked hypophosphatemic rickets (XLH, OMIM #307800) is a rare genetic metabolic disorder caused by dysregulation of fibroblast-like growth factor 23 (FGF23) leading to profound reduction in renal phosphate reabsorption. Impaired growth, severe rickets and complex skeletal deformities are direct consequences of hypophosphatemia representing major symptoms of XLH during childhood. In adults, secondary complications including early development of osteoarthritis substantially impair quality of life and cause significant clinical burden. With the global approval of the monoclonal FGF23 antibody burosumab, a targeted treatment with promising results in phase III studies is available for children with XLH. Nevertheless, complete phenotypic rescue is rarely achieved and remaining multisystemic symptoms demand multidisciplinary specialist care. Coordination of patient management within the major medical disciplines is a mainstay to optimize treatment and reduce disease burden. This review aims to depict different perspectives in XLH patient care in the setting of a multidisciplinary centre of expertise for rare bone diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.